Health Blog

Signs and tests
While the abdomen auscultation with a stethoscope, the doctor may hear high pitched borborigmos at the start of mechanical obstruction. If the obstruction has persisted for a long time or if the gut is very injured borborigmos the decline until finally disappearing.

The paralytic ileus is characterized by reduced or absence of borborigmos.

Among the tests showing occlusion are:

* Abdominal computed tomography
* Abdominal Radiography
* Opaque Enema
* Transit esofagogastroduodenal

The goal of HIV therapy is to reduce the level of virus in the blood levels as low as possible and for as long as possible. Currently available are three different classes of antiretroviral drugs. Treatment guidelines recommend using a combination of at least three drugs to form a single highly active antiretroviral therapy (HAART). Antiviral SOLUTIONS ROCHE Diagnostics accurate diagnosis is essential and a control to ensure sound management of HIV infection. Roche is working on the development and commercialization of diagnostic tests, such as technology of the Chain Reaction Polymerase chain reaction (PCR), which quantifies the levels of HIV in the blood. In 1994, the HIV-1 Amplicor Monitor Roche became the first test market for accurately measuring the exact amounts of HIV-1 RNA in blood ( “viral load”). This remains the only FDA-approved test to measure viral load. It is a highly sensitive test, guaranteed for loads up to 50 copies of viral RNA per ml., Well below the levels of other viral load tests. This degree of accuracy is important to evaluate the success and durability of HIV therapy.
The goal of HIV treatment is to prolong life and improve quality of life for patients living with HIV / AIDS. The drugs currently available achieve these goals by reducing the amount of virus circulating in the body (viral load) at minimum levels and prolonged. As the amount of virus decreases, the immune system tends to recover and thus increases the amount of CD4 + lymphocytes. These results were possible when using combinations of three or four drugs, known as “cocktails” or treatments for high efficiency.
The measurement system of HIV viral load is the most widely Amplicor HIV 1 Monitor, a test capable of detecting a version of 50 copies of viral RNA per milliliter, the sensitivity required for adequate monitoring of treatment of high effectiveness.

Roche continues to invest significantly in research of HIV. Group at Roche Discovery Welwyn, United Kingdom, offers programs in the areas of new protease inhibitors, non-nucleoside inhibitors of reverse transcriptase, as well as chemokines receptor inhibitors (agents that associate with specific sites on the CD4 cell and prevent a virus). In addition, Roche has developed Valganciclovir, a drug that will optimize the treatment of CMV infection when obtaining blood levels of drug orally similar to those obtained by intravenous route.
Roche continued investment in molecular diagnostics will allow the rapid detection and analysis of the HIV virus resistant to mediation, taking into account the treatment is optimized and best use of available resources for people living with HIV / AIDS. Roche is supporting several initiatives (Solutions for Integrated Health Care) in the area of HIV resistance to antiviral drugs that will optimize treatment and improve the use of resources for people receiving treatment for high efficiency. Roche is actively engaged to participate in programs initiated by WHO, UNAIDS and other international organizations to provide access to HIV treatment in developing countries

Roche has been investigated in this highly effective drug development:

* Enfuvirtide – Fuzeon ™: First fusion inhibitor of HIV.

*
Ganciclovir – Cymevene ™: guanine analogue that inhibits the replication of viruses such as cytomegalovirus and herpes virus.

*
Saquinavir – Fortovase ™: selective inhibitors of HIV protease proteinase.

*
Saquinavir sgc – Fortovase ™: protease inhibitor in a new formulation (soft gelatin capsule).

*
Valganciclovir – Valixa ™: VALIXA is indicated for the treatment of induction and maintenance of cytomegalovirus retinitis (CMV retinitis) in patients with acquired immunodeficiency syndrome (AIDS).
VALIXA is also indicated for the prevention of CMV disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donor.

*
Zalcitabine – Hivid ™: Combination therapy with zidovudine (AZT) in patients with advanced HIV.